Systematic review / meta-analysis / 2012
Curcumin reduced clinical and endoscopic activity scores in quiescent ulcerative colitis.
A systematic review identified one randomized trial evaluating 2 g/day of oral curcumin alongside standard therapy in 89 patients with quiescent ulcerative colitis. Relapse occurred in 4% of curcumin patients versus 18% with placebo at six months (RR 0.24, 95% CI 0.05 to 1.09; P = 0.06), with no difference at 12 months (RR 0.70, 95% CI 0.35 to 1.40). At six months, curcumin significantly reduced clinical activity (MD -1.20, 95% CI -2.14 to -0.26) and endoscopic scores (MD -0.80, 95% CI -1.33 to -0.27).
- Study type
- Systematic review of randomized controlled trials
- Who was studied
- 89 patients with quiescent ulcerative colitis (1 trial)
- What was measured
- Relapse rates and clinical and endoscopic activity indices
THE PAPER
Curcumin for maintenance of remission in ulcerative colitis.
Kumar S, Ahuja V, Sankar MJ, Kumar A, Moss AC. Cochrane Database Syst Rev, 2012.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.